Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma.

Critical reviews in oncology/hematology - 1 Apr 2024

Fischer Rachel A, Ryan Isabel, De La Torre Kristine, Barnett Cody, Sehgal Viren S, Levy Joan B, Luke Jason J, Poklepovic Andrew S, Hurlbert Marc S

Abstract excerpt

New treatments have increased survival of patients with melanoma, and methods to monitor patients throughout the disease process are needed. Circulating tumor DNA (ctDNA) is a predictive and prognostic biomarker that may allow routine, real-time monitoring of disease status. We surveyed 44 US physicians to understand their preferences and practice patterns for biomarker and ctDNA testing in their patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 38341119
DOI: 10.1016/j.critrevonc.2024.104289

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma.PMID 38341119Read ↗

Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumorsSemantic proximity Read ↗

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.Semantic proximity Read ↗

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting.Semantic proximity Read ↗

Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma.Semantic proximity Read ↗

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.Semantic proximity Read ↗

Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced MelanomaSemantic proximity Read ↗

Dynamic ctDNA mutational complexity in melanoma patients receiving immunotherapySemantic proximity Read ↗

Release of Cell-Free Tumor DNA in the Plasma of Uveal Melanoma Patients Under Radiotherapy.Semantic proximity Read ↗

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspSemantic proximity Read ↗

Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.Semantic proximity Read ↗

Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.